<div id="readability-page-1"><p>TD Cowen analyst Stacy Ku has maintained their bullish  stance on <span>BCRX</span> stock, giving a Buy rating today.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Stacy Ku has given his Buy rating due to a combination of factors tied mainly to the durable Orladeyo franchise and the company’s attractive valuation. Orladeyo continues to show strong underlying demand with double‑digit year‑over‑year growth, stable prescriber additions, and management reaffirming 2026 revenue guidance of $625–645 million, supported by anticipated pediatric use once a manageable manufacturing issue is resolved.</p> <p>Ku further highlights that BioCryst trades at a notable discount at roughly 2x projected 2027 revenue despite intellectual property protection into 2039 and the potential for both Orladeyo and navenibart to each reach roughly $1 billion in peak HAE sales. Physician feedback indicates Orladeyo should remain the leading oral prophylactic option with strong five‑year patient retention, while navenibart is poised to become a preferred injectable, supporting a long runway of growth and justifying the reiterated $30 price target.</p> <p>Ku covers the Healthcare sector, focusing on stocks such as Supernus Pharmaceuticals, Aurinia Pharmaceuticals, and Protara Therapeutics. According to TipRanks, Ku has an average return of <span>13.8%</span> and a 56.12% success rate on recommended stocks. </p> <p>In another report released today, Needham also maintained a Buy rating on the stock with a $16.00 price target.</p></div>

BCRX

<p>TD Cowen analyst Stacy Ku has reiterated a Buy rating on BioCryst (BCRX) stock, citing the strength of the Orladeyo franchise and the company's attractive valuation. Orladeyo shows strong demand with double-digit growth and stable prescriber additions, with a 2026 revenue guidance of $625–645 million. BioCryst trades at a discount, with potential for significant sales growth. Ku maintains a $30 price target, supported by positive physician feedback and long-term growth prospects. Needham also maintains a Buy rating with a $16 price target.</p>

- TD Cowen analyst Stacy Ku maintains a bullish outlook on BCRX shares, assigning a buy rating due to Orladeyo's strong demand and attractive valuation.  
- Orladeyo shows double-digit year-over-year growth with stable increases in prescriber numbers, supporting revenue guidance of $625 million to $645 million for 2026.  
- Despite BioCryst’s significant discount relative to expected 2027 earnings, Orladeyo and navenibart are projected to peak at approximately $1 billion in HAE sales.

Tip Ranks

BioCryst Pharma

VG Health

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

Direxion S&P Biotech Bull 3X

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

iShares US Pharma

iShares Biotechnology ETF

VanEck Biotech ETF

Toronto Dominion Bank

Supernus Pharma

Aurinia Pharma

Protara Therapeutic

BioCryst Buy Rating Reiterated on Orladeyo Strength, Long-Term Growth Potential and Unchanged $30 Price Target